Marijke Vroomen Durning, RN

The use of chimeric antigen receptor (CAR) T-cell therapies for the treatment of hematologic malignancies is still in its early stages, but when the FDA approved tisagenlecleucel and axicabtagene ciloleucel in 2017, this gave hope to oncologists and patients with some types of leukemia and lymphoma who have exhausted all other options.

After a decade of little movement in the treatment of advanced hepatocellular carcinoma (HCC), there are promising developments on the horizon, according to recent study findings.

As the population of cancer survivors has grown, so has the risk that patients will develop— and succumb to—a second cancer.

Despite advances in the oncology field, venous thromboembolism remains a significant problem for patients with cancer.

Ovarian cancer remains a silent and deadly tumor type with 5-year survival rates that lag far behind those of other gynecologic malignancies. Yet optimism is in the air these days as researchers focus on developing new therapies in 2 key areas: antiangiogenic agents and PARP inhibitors.

Although researchers have been exploring gene editing for more than 40 years, scientists say the CRISPR technology offers game-changing methods for anticancer research as well as a host of other applications.

The RAS family of genes, implicated in more than 30% of human cancers, has proved to be such a difficult molecular driver to target that researchers have considered it "undruggable." A 3-year-old effort by the National Cancer Institute aims to change that—and is making headway.

Researchers and oncologists are excited about the prospect of MRD becoming equally useful in the assessment and management of patients with multiple myeloma, particularly in light of the development of new, more effective therapies and the current limited ability to assess their effectiveness.